Global ADHD Treatment Market
Global ADHD Treatment Market

ADHD Treatment Comprehensive Study by Type (Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine, Guanfacine, Others), Treatment (Medications, Behavior Therapy, Counselling, Education Services, Others), End-User (Retail Pharmacy, Hospital Pharmacy, Clinics), Age (Adult (Aged 18 and above), Children) Players and Region - Global Market Outlook to 2027

ADHD Treatment Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 202 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is ADHD Treatment?
The most common neurodevelopmental illness in children is attention deficit hyperactivity disorder (ADHD). ADHD is typically diagnosed in childhood and persists into adulthood. Children with ADHD may daydream excessively, forget or lose things, have problems resisting temptation, have trouble taking turns, have difficulty getting along with others, be extremely energetic, and have difficulty paying attention. Stimulant and non-stimulant medications are used to treat attention deficit hyperactivity disorder (ADHD).

The market study is broken down by Type (Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine, Guanfacine and Others) and major geographies with country level break-up.

Mergers and acquisitions, expansions, investments, new service launches, and collaborations are among the companies' favoured techniques for exploring the market. Players are expanding and acquiring businesses in new geographies in order to get a competitive edge through synergy. The major key players are contributing there share for increasing company growth. Manufacturers are aiming their products at both children and adults with ADHD. Certain prescriptions are flavoured to make them more appealing to children, whereas the purpose for adults is to offer a long-lasting effect so that they don't have to take as many tablets each day. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amneal Pharmaceuticals, Inc (United States), Eli Lilly and Company (United States), Novartis International AG (Switzerland), Janssen Pharmaceuticals, Inc (Belgium), Mayo Clinic (United States), RespireRx Pharmaceuticals Inc (United States), Otsuka Pharmaceutical Co., Ltd (Japan), Neos Therapeutics, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Noven Pharmaceuticals, Inc (United States) and Purdue Pharma L.P. (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global ADHD Treatment market by Type, Application and Region.

On the basis of geography, the market of ADHD Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medications will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Retail Pharmacy will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age, the sub-segment i.e. Adult (Aged 18 and above) will boost the ADHD Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, The US Food and Drug Administration approved two new ADHD medications in the spring. Qelbree is a nonstimulant drug, while Azstarys is a stimulant. Both are appropriate for children aged six and up.


Market Trend
  • Increasing demand of Azstarys which is stimulant medication

Market Drivers
  • Rising Prevalence of ADHD Treatment
  • Growing Clinical Trials by Companies and Academic Institutes
  • Need for Continuous Cognitive Improvement in Students

Opportunities
  • Increasing the Product's Marketing and Partnership Agreements

Restraints
  • Side-Effects Associated with ADHD Drugs
  • High Cost of ADHD Drugs

Challenges
  • New alternative treatment methods are launched
  • Inappropriate Funding Procedures


About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Amneal Pharmaceuticals, Inc (United States), Eli Lilly and Company (United States), Novartis International AG (Switzerland), Janssen Pharmaceuticals, Inc (Belgium), Mayo Clinic (United States), RespireRx Pharmaceuticals Inc (United States), Otsuka Pharmaceutical Co., Ltd (Japan), Neos Therapeutics, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and GlaxoSmithKline plc (United Kingdom) etc.

2. Can we have customized study for ADHD Treatment Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of ADHD Treatment Market by 2027?
Analysts at AMA estimates ADHD Treatment Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Type
  • Methylphenidate
  • Lisdexamfetamine
  • Dexamfetamine
  • Atomoxetine
  • Guanfacine
  • Others
By Treatment
  • Medications
  • Behavior Therapy
  • Counselling
  • Education Services
  • Others

By End-User
  • Retail Pharmacy
  • Hospital Pharmacy
  • Clinics

By Age
  • Adult (Aged 18 and above)
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of ADHD Treatment
      • 3.2.2. Growing Clinical Trials by Companies and Academic Institutes
      • 3.2.3. Need for Continuous Cognitive Improvement in Students
    • 3.3. Market Challenges
      • 3.3.1. New alternative treatment methods are launched
      • 3.3.2. Inappropriate Funding Procedures
    • 3.4. Market Trends
      • 3.4.1. Increasing demand of Azstarys which is stimulant medication
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global ADHD Treatment, by Type, Treatment, End-User, Age and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global ADHD Treatment (Value)
      • 5.2.1. Global ADHD Treatment by: Type (Value)
        • 5.2.1.1. Methylphenidate
        • 5.2.1.2. Lisdexamfetamine
        • 5.2.1.3. Dexamfetamine
        • 5.2.1.4. Atomoxetine
        • 5.2.1.5. Guanfacine
        • 5.2.1.6. Others
      • 5.2.2. Global ADHD Treatment by: Treatment (Value)
        • 5.2.2.1. Medications
        • 5.2.2.2. Behavior Therapy
        • 5.2.2.3. Counselling
        • 5.2.2.4. Education Services
        • 5.2.2.5. Others
      • 5.2.3. Global ADHD Treatment by: End-User (Value)
        • 5.2.3.1. Retail Pharmacy
        • 5.2.3.2. Hospital Pharmacy
        • 5.2.3.3. Clinics
      • 5.2.4. Global ADHD Treatment by: Age (Value)
        • 5.2.4.1. Adult (Aged 18 and above)
        • 5.2.4.2. Children
      • 5.2.5. Global ADHD Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global ADHD Treatment (Price)
      • 5.3.1. Global ADHD Treatment by: Type (Price)
  • 6. ADHD Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amneal Pharmaceuticals, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Janssen Pharmaceuticals, Inc (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mayo Clinic (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. RespireRx Pharmaceuticals Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Otsuka Pharmaceutical Co., Ltd (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neos Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global ADHD Treatment Sale, by Type, Treatment, End-User, Age and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global ADHD Treatment (Value)
      • 7.2.1. Global ADHD Treatment by: Type (Value)
        • 7.2.1.1. Methylphenidate
        • 7.2.1.2. Lisdexamfetamine
        • 7.2.1.3. Dexamfetamine
        • 7.2.1.4. Atomoxetine
        • 7.2.1.5. Guanfacine
        • 7.2.1.6. Others
      • 7.2.2. Global ADHD Treatment by: Treatment (Value)
        • 7.2.2.1. Medications
        • 7.2.2.2. Behavior Therapy
        • 7.2.2.3. Counselling
        • 7.2.2.4. Education Services
        • 7.2.2.5. Others
      • 7.2.3. Global ADHD Treatment by: End-User (Value)
        • 7.2.3.1. Retail Pharmacy
        • 7.2.3.2. Hospital Pharmacy
        • 7.2.3.3. Clinics
      • 7.2.4. Global ADHD Treatment by: Age (Value)
        • 7.2.4.1. Adult (Aged 18 and above)
        • 7.2.4.2. Children
      • 7.2.5. Global ADHD Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global ADHD Treatment (Price)
      • 7.3.1. Global ADHD Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. ADHD Treatment: by Type(USD Million)
  • Table 2. ADHD Treatment Methylphenidate , by Region USD Million (2016-2021)
  • Table 3. ADHD Treatment Lisdexamfetamine , by Region USD Million (2016-2021)
  • Table 4. ADHD Treatment Dexamfetamine , by Region USD Million (2016-2021)
  • Table 5. ADHD Treatment Atomoxetine , by Region USD Million (2016-2021)
  • Table 6. ADHD Treatment Guanfacine , by Region USD Million (2016-2021)
  • Table 7. ADHD Treatment Others , by Region USD Million (2016-2021)
  • Table 8. ADHD Treatment: by Treatment(USD Million)
  • Table 9. ADHD Treatment Medications , by Region USD Million (2016-2021)
  • Table 10. ADHD Treatment Behavior Therapy , by Region USD Million (2016-2021)
  • Table 11. ADHD Treatment Counselling , by Region USD Million (2016-2021)
  • Table 12. ADHD Treatment Education Services , by Region USD Million (2016-2021)
  • Table 13. ADHD Treatment Others , by Region USD Million (2016-2021)
  • Table 14. ADHD Treatment: by End-User(USD Million)
  • Table 15. ADHD Treatment Retail Pharmacy , by Region USD Million (2016-2021)
  • Table 16. ADHD Treatment Hospital Pharmacy , by Region USD Million (2016-2021)
  • Table 17. ADHD Treatment Clinics , by Region USD Million (2016-2021)
  • Table 18. ADHD Treatment: by Age(USD Million)
  • Table 19. ADHD Treatment Adult (Aged 18 and above) , by Region USD Million (2016-2021)
  • Table 20. ADHD Treatment Children , by Region USD Million (2016-2021)
  • Table 21. South America ADHD Treatment, by Country USD Million (2016-2021)
  • Table 22. South America ADHD Treatment, by Type USD Million (2016-2021)
  • Table 23. South America ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 24. South America ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 25. South America ADHD Treatment, by Age USD Million (2016-2021)
  • Table 26. Brazil ADHD Treatment, by Type USD Million (2016-2021)
  • Table 27. Brazil ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 28. Brazil ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 29. Brazil ADHD Treatment, by Age USD Million (2016-2021)
  • Table 30. Argentina ADHD Treatment, by Type USD Million (2016-2021)
  • Table 31. Argentina ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 32. Argentina ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 33. Argentina ADHD Treatment, by Age USD Million (2016-2021)
  • Table 34. Rest of South America ADHD Treatment, by Type USD Million (2016-2021)
  • Table 35. Rest of South America ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 36. Rest of South America ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 37. Rest of South America ADHD Treatment, by Age USD Million (2016-2021)
  • Table 38. Asia Pacific ADHD Treatment, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific ADHD Treatment, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 41. Asia Pacific ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 42. Asia Pacific ADHD Treatment, by Age USD Million (2016-2021)
  • Table 43. China ADHD Treatment, by Type USD Million (2016-2021)
  • Table 44. China ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 45. China ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 46. China ADHD Treatment, by Age USD Million (2016-2021)
  • Table 47. Japan ADHD Treatment, by Type USD Million (2016-2021)
  • Table 48. Japan ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 49. Japan ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 50. Japan ADHD Treatment, by Age USD Million (2016-2021)
  • Table 51. India ADHD Treatment, by Type USD Million (2016-2021)
  • Table 52. India ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 53. India ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 54. India ADHD Treatment, by Age USD Million (2016-2021)
  • Table 55. South Korea ADHD Treatment, by Type USD Million (2016-2021)
  • Table 56. South Korea ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 57. South Korea ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 58. South Korea ADHD Treatment, by Age USD Million (2016-2021)
  • Table 59. Australia ADHD Treatment, by Type USD Million (2016-2021)
  • Table 60. Australia ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 61. Australia ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 62. Australia ADHD Treatment, by Age USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific ADHD Treatment, by Type USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific ADHD Treatment, by Age USD Million (2016-2021)
  • Table 67. Europe ADHD Treatment, by Country USD Million (2016-2021)
  • Table 68. Europe ADHD Treatment, by Type USD Million (2016-2021)
  • Table 69. Europe ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 70. Europe ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 71. Europe ADHD Treatment, by Age USD Million (2016-2021)
  • Table 72. Germany ADHD Treatment, by Type USD Million (2016-2021)
  • Table 73. Germany ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 74. Germany ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 75. Germany ADHD Treatment, by Age USD Million (2016-2021)
  • Table 76. France ADHD Treatment, by Type USD Million (2016-2021)
  • Table 77. France ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 78. France ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 79. France ADHD Treatment, by Age USD Million (2016-2021)
  • Table 80. Italy ADHD Treatment, by Type USD Million (2016-2021)
  • Table 81. Italy ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 82. Italy ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 83. Italy ADHD Treatment, by Age USD Million (2016-2021)
  • Table 84. United Kingdom ADHD Treatment, by Type USD Million (2016-2021)
  • Table 85. United Kingdom ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 86. United Kingdom ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 87. United Kingdom ADHD Treatment, by Age USD Million (2016-2021)
  • Table 88. Netherlands ADHD Treatment, by Type USD Million (2016-2021)
  • Table 89. Netherlands ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 90. Netherlands ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 91. Netherlands ADHD Treatment, by Age USD Million (2016-2021)
  • Table 92. Rest of Europe ADHD Treatment, by Type USD Million (2016-2021)
  • Table 93. Rest of Europe ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 94. Rest of Europe ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 95. Rest of Europe ADHD Treatment, by Age USD Million (2016-2021)
  • Table 96. MEA ADHD Treatment, by Country USD Million (2016-2021)
  • Table 97. MEA ADHD Treatment, by Type USD Million (2016-2021)
  • Table 98. MEA ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 99. MEA ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 100. MEA ADHD Treatment, by Age USD Million (2016-2021)
  • Table 101. Middle East ADHD Treatment, by Type USD Million (2016-2021)
  • Table 102. Middle East ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 103. Middle East ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 104. Middle East ADHD Treatment, by Age USD Million (2016-2021)
  • Table 105. Africa ADHD Treatment, by Type USD Million (2016-2021)
  • Table 106. Africa ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 107. Africa ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 108. Africa ADHD Treatment, by Age USD Million (2016-2021)
  • Table 109. North America ADHD Treatment, by Country USD Million (2016-2021)
  • Table 110. North America ADHD Treatment, by Type USD Million (2016-2021)
  • Table 111. North America ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 112. North America ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 113. North America ADHD Treatment, by Age USD Million (2016-2021)
  • Table 114. United States ADHD Treatment, by Type USD Million (2016-2021)
  • Table 115. United States ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 116. United States ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 117. United States ADHD Treatment, by Age USD Million (2016-2021)
  • Table 118. Canada ADHD Treatment, by Type USD Million (2016-2021)
  • Table 119. Canada ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 120. Canada ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 121. Canada ADHD Treatment, by Age USD Million (2016-2021)
  • Table 122. Mexico ADHD Treatment, by Type USD Million (2016-2021)
  • Table 123. Mexico ADHD Treatment, by Treatment USD Million (2016-2021)
  • Table 124. Mexico ADHD Treatment, by End-User USD Million (2016-2021)
  • Table 125. Mexico ADHD Treatment, by Age USD Million (2016-2021)
  • Table 126. ADHD Treatment: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. ADHD Treatment: by Type(USD Million)
  • Table 138. ADHD Treatment Methylphenidate , by Region USD Million (2022-2027)
  • Table 139. ADHD Treatment Lisdexamfetamine , by Region USD Million (2022-2027)
  • Table 140. ADHD Treatment Dexamfetamine , by Region USD Million (2022-2027)
  • Table 141. ADHD Treatment Atomoxetine , by Region USD Million (2022-2027)
  • Table 142. ADHD Treatment Guanfacine , by Region USD Million (2022-2027)
  • Table 143. ADHD Treatment Others , by Region USD Million (2022-2027)
  • Table 144. ADHD Treatment: by Treatment(USD Million)
  • Table 145. ADHD Treatment Medications , by Region USD Million (2022-2027)
  • Table 146. ADHD Treatment Behavior Therapy , by Region USD Million (2022-2027)
  • Table 147. ADHD Treatment Counselling , by Region USD Million (2022-2027)
  • Table 148. ADHD Treatment Education Services , by Region USD Million (2022-2027)
  • Table 149. ADHD Treatment Others , by Region USD Million (2022-2027)
  • Table 150. ADHD Treatment: by End-User(USD Million)
  • Table 151. ADHD Treatment Retail Pharmacy , by Region USD Million (2022-2027)
  • Table 152. ADHD Treatment Hospital Pharmacy , by Region USD Million (2022-2027)
  • Table 153. ADHD Treatment Clinics , by Region USD Million (2022-2027)
  • Table 154. ADHD Treatment: by Age(USD Million)
  • Table 155. ADHD Treatment Adult (Aged 18 and above) , by Region USD Million (2022-2027)
  • Table 156. ADHD Treatment Children , by Region USD Million (2022-2027)
  • Table 157. South America ADHD Treatment, by Country USD Million (2022-2027)
  • Table 158. South America ADHD Treatment, by Type USD Million (2022-2027)
  • Table 159. South America ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 160. South America ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 161. South America ADHD Treatment, by Age USD Million (2022-2027)
  • Table 162. Brazil ADHD Treatment, by Type USD Million (2022-2027)
  • Table 163. Brazil ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 164. Brazil ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 165. Brazil ADHD Treatment, by Age USD Million (2022-2027)
  • Table 166. Argentina ADHD Treatment, by Type USD Million (2022-2027)
  • Table 167. Argentina ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 168. Argentina ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 169. Argentina ADHD Treatment, by Age USD Million (2022-2027)
  • Table 170. Rest of South America ADHD Treatment, by Type USD Million (2022-2027)
  • Table 171. Rest of South America ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 172. Rest of South America ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 173. Rest of South America ADHD Treatment, by Age USD Million (2022-2027)
  • Table 174. Asia Pacific ADHD Treatment, by Country USD Million (2022-2027)
  • Table 175. Asia Pacific ADHD Treatment, by Type USD Million (2022-2027)
  • Table 176. Asia Pacific ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 177. Asia Pacific ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 178. Asia Pacific ADHD Treatment, by Age USD Million (2022-2027)
  • Table 179. China ADHD Treatment, by Type USD Million (2022-2027)
  • Table 180. China ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 181. China ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 182. China ADHD Treatment, by Age USD Million (2022-2027)
  • Table 183. Japan ADHD Treatment, by Type USD Million (2022-2027)
  • Table 184. Japan ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 185. Japan ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 186. Japan ADHD Treatment, by Age USD Million (2022-2027)
  • Table 187. India ADHD Treatment, by Type USD Million (2022-2027)
  • Table 188. India ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 189. India ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 190. India ADHD Treatment, by Age USD Million (2022-2027)
  • Table 191. South Korea ADHD Treatment, by Type USD Million (2022-2027)
  • Table 192. South Korea ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 193. South Korea ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 194. South Korea ADHD Treatment, by Age USD Million (2022-2027)
  • Table 195. Australia ADHD Treatment, by Type USD Million (2022-2027)
  • Table 196. Australia ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 197. Australia ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 198. Australia ADHD Treatment, by Age USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific ADHD Treatment, by Type USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific ADHD Treatment, by Age USD Million (2022-2027)
  • Table 203. Europe ADHD Treatment, by Country USD Million (2022-2027)
  • Table 204. Europe ADHD Treatment, by Type USD Million (2022-2027)
  • Table 205. Europe ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 206. Europe ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 207. Europe ADHD Treatment, by Age USD Million (2022-2027)
  • Table 208. Germany ADHD Treatment, by Type USD Million (2022-2027)
  • Table 209. Germany ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 210. Germany ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 211. Germany ADHD Treatment, by Age USD Million (2022-2027)
  • Table 212. France ADHD Treatment, by Type USD Million (2022-2027)
  • Table 213. France ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 214. France ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 215. France ADHD Treatment, by Age USD Million (2022-2027)
  • Table 216. Italy ADHD Treatment, by Type USD Million (2022-2027)
  • Table 217. Italy ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 218. Italy ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 219. Italy ADHD Treatment, by Age USD Million (2022-2027)
  • Table 220. United Kingdom ADHD Treatment, by Type USD Million (2022-2027)
  • Table 221. United Kingdom ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 222. United Kingdom ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 223. United Kingdom ADHD Treatment, by Age USD Million (2022-2027)
  • Table 224. Netherlands ADHD Treatment, by Type USD Million (2022-2027)
  • Table 225. Netherlands ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 226. Netherlands ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 227. Netherlands ADHD Treatment, by Age USD Million (2022-2027)
  • Table 228. Rest of Europe ADHD Treatment, by Type USD Million (2022-2027)
  • Table 229. Rest of Europe ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 230. Rest of Europe ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 231. Rest of Europe ADHD Treatment, by Age USD Million (2022-2027)
  • Table 232. MEA ADHD Treatment, by Country USD Million (2022-2027)
  • Table 233. MEA ADHD Treatment, by Type USD Million (2022-2027)
  • Table 234. MEA ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 235. MEA ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 236. MEA ADHD Treatment, by Age USD Million (2022-2027)
  • Table 237. Middle East ADHD Treatment, by Type USD Million (2022-2027)
  • Table 238. Middle East ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 239. Middle East ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 240. Middle East ADHD Treatment, by Age USD Million (2022-2027)
  • Table 241. Africa ADHD Treatment, by Type USD Million (2022-2027)
  • Table 242. Africa ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 243. Africa ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 244. Africa ADHD Treatment, by Age USD Million (2022-2027)
  • Table 245. North America ADHD Treatment, by Country USD Million (2022-2027)
  • Table 246. North America ADHD Treatment, by Type USD Million (2022-2027)
  • Table 247. North America ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 248. North America ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 249. North America ADHD Treatment, by Age USD Million (2022-2027)
  • Table 250. United States ADHD Treatment, by Type USD Million (2022-2027)
  • Table 251. United States ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 252. United States ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 253. United States ADHD Treatment, by Age USD Million (2022-2027)
  • Table 254. Canada ADHD Treatment, by Type USD Million (2022-2027)
  • Table 255. Canada ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 256. Canada ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 257. Canada ADHD Treatment, by Age USD Million (2022-2027)
  • Table 258. Mexico ADHD Treatment, by Type USD Million (2022-2027)
  • Table 259. Mexico ADHD Treatment, by Treatment USD Million (2022-2027)
  • Table 260. Mexico ADHD Treatment, by End-User USD Million (2022-2027)
  • Table 261. Mexico ADHD Treatment, by Age USD Million (2022-2027)
  • Table 262. ADHD Treatment: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global ADHD Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global ADHD Treatment: by Treatment USD Million (2016-2021)
  • Figure 6. Global ADHD Treatment: by End-User USD Million (2016-2021)
  • Figure 7. Global ADHD Treatment: by Age USD Million (2016-2021)
  • Figure 8. South America ADHD Treatment Share (%), by Country
  • Figure 9. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 10. Europe ADHD Treatment Share (%), by Country
  • Figure 11. MEA ADHD Treatment Share (%), by Country
  • Figure 12. North America ADHD Treatment Share (%), by Country
  • Figure 13. Global ADHD Treatment: by Type USD/Units (2016-2021)
  • Figure 14. Global ADHD Treatment share by Players 2021 (%)
  • Figure 15. Global ADHD Treatment share by Players (Top 3) 2021(%)
  • Figure 16. Global ADHD Treatment share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Amneal Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amneal Pharmaceuticals, Inc (United States) Revenue: by Geography 2021
  • Figure 20. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 22. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 24. Janssen Pharmaceuticals, Inc (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. Janssen Pharmaceuticals, Inc (Belgium) Revenue: by Geography 2021
  • Figure 26. Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mayo Clinic (United States) Revenue: by Geography 2021
  • Figure 28. RespireRx Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 29. RespireRx Pharmaceuticals Inc (United States) Revenue: by Geography 2021
  • Figure 30. Otsuka Pharmaceutical Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Otsuka Pharmaceutical Co., Ltd (Japan) Revenue: by Geography 2021
  • Figure 32. Neos Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Neos Therapeutics, Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2021
  • Figure 36. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2021
  • Figure 38. Global ADHD Treatment: by Type USD Million (2022-2027)
  • Figure 39. Global ADHD Treatment: by Treatment USD Million (2022-2027)
  • Figure 40. Global ADHD Treatment: by End-User USD Million (2022-2027)
  • Figure 41. Global ADHD Treatment: by Age USD Million (2022-2027)
  • Figure 42. South America ADHD Treatment Share (%), by Country
  • Figure 43. Asia Pacific ADHD Treatment Share (%), by Country
  • Figure 44. Europe ADHD Treatment Share (%), by Country
  • Figure 45. MEA ADHD Treatment Share (%), by Country
  • Figure 46. North America ADHD Treatment Share (%), by Country
  • Figure 47. Global ADHD Treatment: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Amneal Pharmaceuticals, Inc (United States)
  • Eli Lilly and Company (United States)
  • Novartis International AG (Switzerland)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Mayo Clinic (United States)
  • RespireRx Pharmaceuticals Inc (United States)
  • Otsuka Pharmaceutical Co., Ltd (Japan)
  • Neos Therapeutics, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GlaxoSmithKline plc (United Kingdom)
Additional players considered in the study are as follows:
Noven Pharmaceuticals, Inc (United States) , Purdue Pharma L.P. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation